<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03275883</url>
  </required_header>
  <id_info>
    <org_study_id>2016-01889</org_study_id>
    <nct_id>NCT03275883</nct_id>
  </id_info>
  <brief_title>Arterial Patency in Liver Transplantation</brief_title>
  <official_title>Retrospective Analysis to Identify Independent Predictive Risk Factors for Early and Late Arterial Occlusion in Liver Transplantation and Compare Short and Long-term Outcomes for Aorto-hepatic Conduits in Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Birmingham NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bologna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leeds Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the risk profile of hepatic artery occlusion in liver&#xD;
      transplant recipients who received an aortohepatic conduits, analyzing all consecutive&#xD;
      cadaveric liver transplantations from July 2007 to 31st December 2016. Medical records will&#xD;
      be examined and adverse events will be analyzed and categorized using the Clavien-Dindo&#xD;
      classification and Comprehensive Complication Index.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND&#xD;
&#xD;
      Arterial conduits in liver transplantation are almost as old as the procedure itself. First&#xD;
      described by Starzl in 1984, the knowledge remains superficial. Although rarely performed,&#xD;
      there is no doubt that thousands of patients' lives were saved because of the use of arterial&#xD;
      grafts. However, arterial grafts are known to be associated with a higher rate of occlusion&#xD;
      and a lower patient and graft survival when compared to conventional end-to-end anastomosis.&#xD;
      In our recent retrospective study, the investigators showed that retransplantation procedure&#xD;
      and aspirin in patients' medication are independent risk factors for the need of an arterial&#xD;
      conduit. The investigators assume that aspirin could be a surrogate marker for vascular and&#xD;
      metabolic status. Furthermore, in a meta-analysis the investigators found a four times higher&#xD;
      occlusion rate compared to non-conduits.&#xD;
&#xD;
      Whether the site of conduit placement or certain types of material have an impact on&#xD;
      occlusion and graft survival remains unknown. In addition, several studies discuss that&#xD;
      antiaggregation or anticoagulation might be protective for occlusion of arterial conduits.&#xD;
      Currently, there is no study that investigated this problem, most probably because of low&#xD;
      case numbers.&#xD;
&#xD;
      STUDY OBJECTIVES&#xD;
&#xD;
      The primary goal of this study is to conduct a multicenter cohort analysis to define the&#xD;
      outcome of different types of conduits and to investigate whether antiplatelet /&#xD;
      anticoagulantion has an impact on patency rates.&#xD;
&#xD;
        1. Specific aim #1: To identify independent risk factors for early and late occlusion of&#xD;
           arterial conduits in liver transplantation.&#xD;
&#xD;
        2. Specific aim #2: To compare different placement sites (infrarenal, supraceliac, iliacal,&#xD;
           etc.) of arterial conduits in terms of occlusion rates and graft survival.&#xD;
&#xD;
        3. Specific aim #3: To investigate whether antiplatelet therapy is protective in terms of&#xD;
           arterial patency.&#xD;
&#xD;
      STUDY DESIGN&#xD;
&#xD;
      This will be a multicenter single cohort study including only cases of deceased donor liver&#xD;
      transplantation that required an aorto-hepatic or iliac-hepatic conduit for arterial&#xD;
      reconstruction. Primary endpoint is 30-day conduit patency. Secondary endpoints include&#xD;
      postoperative complications, death, late conduit occlusion, graft and patient survival.&#xD;
&#xD;
      SETTING&#xD;
&#xD;
      This multicenter cohort study will include several high-volume centers worldwide. Each&#xD;
      participating center requires a prospective database from that data can be extracted. All&#xD;
      consecutive cases of deceased donor liver transplantation requiring an arterial conduit from&#xD;
      1st of January 2007 until 31st of December 2016 are included allowing a minimum follow-up&#xD;
      time of 6 months. Data collection at conduit4olt.org will be prospective, structured,&#xD;
      anonymized, and encrypted.&#xD;
&#xD;
      INSTITUTIONAL REVIEW POLICY / ETHICAL POLICY&#xD;
&#xD;
      Each participating center is responsible to contact their local ethics committee and receive&#xD;
      approval for participation, if applicable. For example, this project is considered as an&#xD;
      audit in some countries and thus there is no need for formal approval in the form of a&#xD;
      protocol submission.&#xD;
&#xD;
      ELIGIBILITY CRITERIA&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        -  Liver transplantation requiring aorto-hepatic or iliac-hepatic conduits&#xD;
&#xD;
        -  Deceased donor after brain death (DBD) or deceased donor after circulatory death (DCD)&#xD;
&#xD;
        -  Whole organ as well as split allografts&#xD;
&#xD;
        -  Primary liver transplantation as well as liver retransplantation&#xD;
&#xD;
        -  Recipient age â‰¥18 years&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  Living donor liver transplantation&#xD;
&#xD;
        -  Pediatric liver transplantation (recipient age &lt;18 years)&#xD;
&#xD;
        -  Arterial reconstruction other than aorto-hepatic or iliac-hepatic conduits&#xD;
&#xD;
        -  Multivisceral transplantations&#xD;
&#xD;
      ESTIMATED SAMPLE SIZE&#xD;
&#xD;
      Each center should provide at least 30 cases that meet the inclusion criteria to allow&#xD;
      adequate event rates for each outcome.&#xD;
&#xD;
      Statistical methods&#xD;
&#xD;
      The primary and secondary endpoints will be compared with patient and operation&#xD;
      characteristics with univariate analysis. ROC Curve analysis will be performed to dichotomize&#xD;
      continuous variables. Multivariable analysis (binary logistic and Cox regression) will be&#xD;
      performed to identify independent risk factors. Statistical analysis will be performed using&#xD;
      R Studio version 1.0.44 (RStudio, Inc. GNU Affero General Public License v3, Boston, MA,&#xD;
      2016) with the graphical user interface rBiostatistics.com beta version (rBiostatistics.com,&#xD;
      Zurich, Switzerland, 2016, GNU License).&#xD;
&#xD;
      Christian E. Oberkofler Tim Reese Dimitri A. Raptis Henrik Petrowsky&#xD;
&#xD;
      On behalf of the conduit4olt.org team Swiss HPB Center, Department of Surgery and&#xD;
      Transplantation, University Hospital Zurich, Switzerland&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">September 5, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Independent risk factors</measure>
    <time_frame>June 2007 til 31st December 2016</time_frame>
    <description>To identify independent risk factors for early and late occlusion of arterial conduits in liver transplantation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Placement sites</measure>
    <time_frame>June 2007 til 31st December 2016</time_frame>
    <description>To compare different placement sites (infrarenal, supraceliac, iliacal, etc.) of arterial conduits in terms of occlusion rates and graft survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patency Rates</measure>
    <time_frame>June 2007 til 31st December 2016</time_frame>
    <description>To investigate whether antiplatelet therapy is protective in terms of arterial patency.</description>
  </primary_outcome>
  <enrollment type="Actual">567</enrollment>
  <condition>Aortohepatic Conduit</condition>
  <condition>Patency Rate</condition>
  <condition>Liver Transplantation</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Aortohepatic Conduit</intervention_name>
    <description>Placement of an interposition graft between hepatic artery and aorta during liver transplantation</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who recieved an aorto-hepatic conduit during liver transplantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Liver transplantation requiring aorto-hepatic or iliac-hepatic conduits&#xD;
&#xD;
          -  Deceased donor after brain death (DBD) or deceased donor after circulatory death (DCD)&#xD;
&#xD;
          -  Whole organ as well as split allografts&#xD;
&#xD;
          -  Primary liver transplantation as well as liver retransplantation&#xD;
&#xD;
          -  Recipient age â‰¥18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Living donor liver transplantation&#xD;
&#xD;
          -  Pediatric liver transplantation (recipient age &lt;18 years)&#xD;
&#xD;
          -  Arterial reconstruction other than aorto-hepatic or iliac-hepatic conduits&#xD;
&#xD;
          -  Multivisceral transplantations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>ZÃ¼rich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2017</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all collected IPD, all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_url>http://conduit4olt.org</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

